Adult-Onset Still's Disease — Structured Data
AI-optimized single page. All data for Adult-Onset Still's Disease in dense, structured format. Last updated: 2026-03-30.
View interactive disease hub · View all sources
Key Statistics
- Total reported cases
- Unknown
- Mean onset age
- 36 years
- Onset range
- 16–75 years
- Sex ratio (M:F)
- 1:1.2
- Diagnostic delay
- ~1 years
- Discovered
- 1971 (Eric Bywaters)
- Prevalence
- <1/1,000,000
- Classification
- autoinflammatory
- Pathophysiology
- partially understood
- Treatment status
- effective options available
- Genetic basis
- under investigation
- Aliases
- AOSD, Adult Still's Disease, Still's Disease (Adult Form), Adult-Onset Still Disease
Symptoms (14)
| Symptom | Frequency | Severity | Category | Description |
|---|---|---|---|---|
| Quotidian spiking fever | 95% | cardinal | systemic | Daily or twice-daily temperature spikes to ≥39°C (102.2°F), typically peaking in the late afternoon or evening and returning to normal or below normal. The quotidian (daily) pattern is characteristic and distinguishes AOSD from other causes of fever of unknown origin. |
| Salmon-colored evanescent rash | 85% | cardinal | dermatologic | Transient, salmon-pink maculopapular rash that characteristically appears during fever spikes and fades when temperature normalizes. Typically affects the trunk and proximal extremities. Non-pruritic in most cases, may exhibit the Koebner phenomenon (appearing at sites of skin pressure or trauma). |
| Arthralgia or arthritis | 90% | cardinal | musculoskeletal | Joint involvement ranges from transient arthralgia during febrile episodes to destructive polyarthritis resembling rheumatoid arthritis. Commonly affects wrists, knees, and ankles. May be the dominant feature in the chronic articular phenotype, potentially leading to joint erosion and functional impairment. |
| Hyperferritinemia | 70% | cardinal | laboratory | Markedly elevated serum ferritin levels, often >1,000 ng/mL and sometimes >10,000 ng/mL, with a characteristically low glycosylated ferritin fraction (<20%). Ferritin correlates with disease activity and is used for both diagnosis and monitoring. Five-fold elevation of ferritin is 41% sensitive and 80% specific for AOSD. |
| Leukocytosis with neutrophilia | 80% | major | laboratory | White blood cell count elevated >10,000/mm³ with predominant neutrophilia (>80% PMNs). Leukocytosis is a major criterion in the Yamaguchi classification and reflects the intense innate immune activation characteristic of AOSD. |
| Sore throat / Pharyngitis | 60% | minor | systemic | Non-exudative pharyngitis that may be the initial presenting symptom, often leading to initial misdiagnosis as a viral or bacterial infection. Throat cultures are characteristically negative. A minor criterion in the Yamaguchi classification. |
| Lymphadenopathy | 50% | minor | systemic | Lymph node enlargement present in 42-56% of patients, frequently involving cervical lymph nodes. May raise suspicion of lymphoma and frequently requires biopsy to exclude malignancy. Histopathology typically shows reactive hyperplasia. |
| Hepatosplenomegaly | 45% | minor | systemic | Hepatomegaly in 12-45% and splenomegaly in 25-55% of patients. Liver involvement may manifest as modest elevation of hepatic transaminases and alkaline phosphatase. Rarely, fulminant hepatitis may occur as a life-threatening complication. |
| Liver dysfunction / Elevated transaminases | 60% | major | laboratory | Elevated hepatic transaminases (AST, ALT) and alkaline phosphatase levels reflecting hepatic inflammation. Usually modest elevations, but severe hepatitis can occur. A minor criterion in the Yamaguchi criteria. NSAIDs and methotrexate can exacerbate liver dysfunction. |
| Myalgia | 50% | minor | musculoskeletal | Diffuse muscle pain often accompanying febrile episodes. May be severe during disease flares and can contribute significantly to disability and reduced quality of life. |
| Serositis (pleuritis/pericarditis) | 30% | major | systemic | Pleuritis and pericarditis may occur in 30-40% of patients. Pleural effusions and pericardial effusions are usually mild to moderate. Rarely, cardiac tamponade may develop as a life-threatening complication requiring urgent intervention. |
| Elevated ESR and CRP | 95% | major | laboratory | Erythrocyte sedimentation rate and C-reactive protein are markedly elevated in active disease, reflecting systemic inflammation. CRP may exceed 100 mg/L during flares. These are used for monitoring disease activity and treatment response. |
| Negative RF and ANA | 90% | minor | laboratory | Absence of rheumatoid factor and antinuclear antibody is characteristic of AOSD and is a minor criterion in the Yamaguchi classification. Their presence should prompt consideration of alternative diagnoses such as rheumatoid arthritis or systemic lupus erythematosus. |
| Weight loss | 25% | minor | systemic | Unintentional weight loss may occur during active disease due to systemic inflammation, reduced appetite, and catabolic state. Can contribute to the diagnostic workup for malignancy. |
Molecular Pathway (9 molecules)
| Molecule | Role | Expression change | Evidence level | Targeted by | Explanation |
|---|---|---|---|---|---|
| IL-1β | Central pro-inflammatory cytokine driving systemic inflammation | Elevated | established | Anakinra, Canakinumab | IL-1β is a key effector cytokine in AOSD, produced by NLRP3 inflammasome-mediated caspase-1 cleavage of pro-IL-1β. Drives fever, arthritis, rash, and acute-phase response. The dramatic efficacy of IL-1 blockade (anakinra, canakinumab) confirms its central pathogenic role. Both anakinra and canakinumab have received EMA approval for AOSD based on IL-1β's established role. |
| IL-18 | Key cytokine uniquely elevated in AOSD; drives MAS and IFN-γ production | Markedly elevated (up to 1000-fold) | established | Tadekinig alfa (IL-18BP) | IL-18 serum levels in active AOSD can be up to 1000-fold higher than in other rheumatic diseases — the highest levels reported for any disease. IL-18 drives Th1 polarization, IFN-γ production, macrophage activation, and is closely linked to MAS development. Free IL-18 (not bound to IL-18BP) is specifically elevated in AOSD vs other inflammatory diseases. IL-18 serves as a diagnostic biomarker, disease activity marker, and potential therapeutic target. |
| IL-6 | Pleiotropic cytokine driving acute-phase response and joint destruction | Elevated | established | Tocilizumab | IL-6 serum levels are highly increased in both systemic and chronic articular AOSD phenotypes. IL-6 drives hepatic production of ferritin, CRP, and other acute-phase reactants, contributes to fever, and promotes joint destruction via osteoclast activation. IL-6 blockade with tocilizumab is particularly effective for the chronic articular phenotype and enables glucocorticoid sparing. |
| NLRP3 inflammasome | Central innate immune sensor driving caspase-1 activation and IL-1β/IL-18 maturation | Overexpressed and hyperactivated | established | — | The NLRP3 inflammasome is excessively activated in AOSD patients. Upon stimulation by DAMPs and PAMPs through TLRs, NLRP3 recruits ASC adaptor proteins and activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into bioactive forms. NLRP3, caspase-1, and IL-1β expression are all significantly elevated in PBMCs from AOSD patients. NLRP3 inhibition reduces IL-1β and IL-18 protein expression in AOSD PBMCs. |
| TNF-α | Pro-inflammatory cytokine contributing to systemic inflammation | Elevated | strong | Infliximab, Etanercept | TNF-α is elevated in sera and tissues of AOSD patients regardless of disease activity. It contributes to systemic inflammation, ferritin production, and joint damage. However, TNF-α blockade (infliximab, etanercept) has shown inconsistent results in AOSD, suggesting it is not the primary driver but rather a downstream effector. |
| IFN-γ | Th1 cytokine linking innate and adaptive immunity; drives macrophage activation | Elevated | strong | — | IFN-γ production is driven by IL-18 stimulation of Th1 cells and NK cells. IFN-γ further activates macrophages, upregulates ferritin synthesis, and plays a central role in the development of macrophage activation syndrome (MAS). Dysfunctional NK cells and elevated Th1 cells contribute to the IFN-γ-driven inflammatory milieu. |
| Caspase-1 | Effector protease of the inflammasome; cleaves pro-IL-1β and pro-IL-18 | Upregulated | strong | — | Caspase-1 is the key enzymatic effector of the NLRP3 inflammasome complex. Its upregulated activity in AOSD leads to proteolytic processing of pro-IL-1β and pro-IL-18 into their bioactive forms, initiating the cytokine storm. Caspase-1 activity is significantly elevated in AOSD PBMCs. |
| S100A8/A9 (Calprotectin) | Alarmin and DAMP released by activated phagocytes; amplifies TLR4 signaling | Elevated | moderate | — | Calprotectin (S100A8/A9 heterodimer) is released by activated neutrophils and macrophages. It activates TLR4 signaling, further stimulating the innate immune cascade. Serum calprotectin is significantly elevated in active AOSD, correlates with disease activity and severity, and decreases after treatment. Serves as a promising disease activity biomarker. |
| Ferritin | Acute-phase reactant and hallmark biomarker; synthesis driven by multiple cytokines | Markedly elevated | established | — | Hyperferritinemia is a hallmark of AOSD, with levels often exceeding 1,000 ng/mL. Ferritin synthesis is upregulated at transcriptional and translational levels by IL-1β, IL-6, IL-18, TNF-α, IFN-γ, and M-CSF. The low glycosylated fraction (<20%) reflects saturated glycosylation during massive hepatic production. Ferritin serves as a diagnostic marker, disease activity indicator, and predictor of MAS and poor prognosis. |
Genetic Findings (5)
| Gene | Variant | Type | Frequency in disease | Significance | Also found in |
|---|---|---|---|---|---|
| HLA-DRB1 | HLA-DRB1*15:01, HLA-DR4, HLA-DR5 (population-dependent) | germline | Variable by population: DRB1*15:01 enriched in Japanese; DR4 in 35% of Dutch patients; B17/B18/B35/DR2 in French | HLA class II associations suggest involvement of adaptive immune system alongside innate immunity, unique among autoinflammatory diseases | Rheumatoid arthritis (HLA-DR4 in 60-70%); Multiple sclerosis (HLA-DRB1*15:01 in 30-40%) |
| IL18 | Promoter polymorphisms (S01/S01 diplotype); -607 promoter polymorphism | germline | S01/S01 diplotype significantly enriched in AOSD patients; seven SNPs and one 9bp insertion identified | IL-18 gene promoter polymorphisms represent a major genetic risk factor for AOSD susceptibility, correlating with the characteristically elevated IL-18 serum levels | Systemic JIA (Similar associations reported) |
| MEFV | Multiple variants including common FMF-associated mutations (E148Q, M694V, etc.) | germline | 15-63% carry variants depending on population (53% in Korean, 63% in Japanese, 15-28% in Caucasian) | Elevated MEFV variant frequency suggests genetic overlap between AOSD and hereditary periodic fever syndromes, supporting the autoinflammatory disease continuum | Familial Mediterranean Fever (Homozygous in >80%); Schnitzler Syndrome (Emerging (2024-2025)) |
| TNFRSF1A | Rare variants associated with AOSD | germline | Rare; particularly relevant in patients with severe/refractory disease courses | TNFRSF1A is the causative gene for TRAPS (TNF receptor-associated periodic syndrome); its association with AOSD further supports genetic overlap with monogenic autoinflammatory diseases | TRAPS (Causative (autosomal dominant)); Other periodic fevers (Variable) |
| MIF | Functional promoter polymorphisms | germline | Polymorphisms associated with disease susceptibility in some populations | Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that may contribute to AOSD pathogenesis through macrophage activation | Rheumatoid arthritis (Associated); Systemic lupus erythematosus (Associated) |
Treatment Evidence Matrix (7 treatments)
| Drug | Mechanism | Route | Response rate | Onset | IgM effect | Line | Explanation |
|---|---|---|---|---|---|---|---|
| NSAIDs | Cyclooxygenase inhibition; anti-inflammatory and antipyretic | Oral (various) | <20% | Days | No direct effect | 1st | First-line for mild disease (fever, arthralgia, myalgia) but effective as monotherapy in fewer than 20% of patients. Most patients require escalation to corticosteroids. Aspirin and indomethacin historically used. Risk of hepatotoxicity in AOSD patients with liver involvement. |
| Corticosteroids (Prednisone) | Broad immunosuppression via NF-kB inhibition and anti-inflammatory gene transcription | Oral 0.5-1 mg/kg/day; IV pulse for severe flares | ~60% | Days | Rapid ferritin reduction | 1st | Mainstay of initial treatment, controlling about 60% of patients. High-dose regimens (1 mg/kg/day prednisone) are more effective than low-dose as first-line and may promote a monocyclic disease course. However, approximately 45% of patients develop steroid dependency, necessitating steroid-sparing agents. IV methylprednisolone pulses used for severe systemic disease and MAS. |
| Methotrexate | Folate antagonist; anti-inflammatory via adenosine pathway modulation | Oral or SC 7.5-20 mg/week | Up to 70% | Weeks to months | No direct effect | 2nd | Most widely used conventional DMARD as steroid-sparing agent. Achieves remission in up to 70% of patients, particularly effective for the chronic articular phenotype. Requires monitoring for hepatotoxicity, which may be exacerbated in AOSD patients with baseline liver dysfunction. Folic acid supplementation recommended. |
| Anakinra | IL-1 receptor antagonist | SC 100 mg daily | ~80-90% | Hours to days | Rapid ferritin reduction | 2nd | Recombinant IL-1 receptor antagonist with rapid onset of action. Fever and systemic symptoms often resolve within hours to days. The first RCT (Nordstrom et al. 2012) demonstrated greater remission rates vs DMARDs. Long-term retention rate is excellent with cumulative loss-of-efficacy risk of only 3.4% at 12 months and 13.5% at 60 months. EMA-approved for AOSD. Particularly effective for the systemic phenotype. Expert consensus is shifting toward early biologic use to reduce steroid burden. |
| Canakinumab | Anti-IL-1beta monoclonal antibody | SC 150-300 mg every 4 weeks | ~67% | Days to weeks | Rapid ferritin reduction | 2nd | Long-acting anti-IL-1beta monoclonal antibody. The CONSIDER phase II RCT showed 67% response (vs 41% placebo). Received EMA conditional marketing authorization for Still's disease (including AOSD) in 2020. FDA approved canakinumab for sJIA in 2013 but has not granted a separate AOSD indication. Advantage over anakinra is less frequent dosing (monthly vs daily). Effective for both systemic and articular manifestations. |
| Tocilizumab | Anti-IL-6 receptor monoclonal antibody | IV 8 mg/kg every 2-4 weeks or SC 162 mg weekly | ~61% (ACR50) | Weeks | Moderate ferritin reduction | 2nd | IL-6 receptor blockade is particularly effective for the chronic articular phenotype with joint-predominant disease. The Kaneko et al. RCT (2018) demonstrated significant improvement in systemic feature score (p=0.003) and glucocorticoid sparing (p=0.017), with ACR50 at week 4 of 61.5% vs 30.8% placebo. IL-6 blockade reduces CRP, ferritin, and hepatic acute-phase reactant production. May be preferred over IL-1 blockade when arthritis dominates the clinical picture. |
| Cyclosporine A | Calcineurin inhibitor; suppresses T-cell activation and cytokine production | Oral 2-5 mg/kg/day | Variable | Days to weeks | No direct effect | Alternative | Particularly valuable in the treatment of AOSD-associated macrophage activation syndrome (MAS), where it helps control the hyperinflammatory state by suppressing T-cell and macrophage activation. Also used as a steroid-sparing agent in refractory systemic disease. Requires monitoring of renal function and blood pressure. Often combined with corticosteroids for MAS management. |
Diagnostic Criteria
Yamaguchi Criteria (1992)
Sensitivity: 96.2% · Specificity: 92.1%
Major criteria (all required)
- Fever >=39 degrees C lasting >=1 week
- Arthralgia or arthritis lasting >=2 weeks
- Typical rash: nonpruritic, salmon-colored, macular or maculopapular, usually appearing during fever
- Leukocytosis >=10,000/mm3 with >=80% granulocytes
Minor criteria (5+ required)
- Sore throat
- Lymphadenopathy and/or splenomegaly
- Liver dysfunction (elevated transaminases and/or LDH)
- Negative ANA and negative RF
Requires 5 or more criteria with at least 2 major criteria. Exclusion of infections (especially sepsis and EBV), malignancies (especially lymphoma), and other autoimmune diseases (especially polyarteritis nodosa and RA with extra-articular features) is mandatory. The most widely used and most sensitive classification criteria for AOSD.
Fautrel Criteria (2002)
Sensitivity: 80.6% · Specificity: 98.5%
Major criteria (all required)
- Spiking fever >=39 degrees C
- Arthralgia
- Transient erythema
- Pharyngitis
- PMN >=80%
- Glycosylated ferritin <=20%
Minor criteria (4+ required)
- Maculopapular rash
- Leukocytosis >=10,000/mm3
Requires 4 or more major criteria, or 3 major plus 2 minor criteria. Does not require exclusion of other diseases, which is a practical advantage over Yamaguchi criteria. Incorporates glycosylated ferritin (<=20%), which is highly specific for AOSD. Higher specificity but lower sensitivity than Yamaguchi criteria.
Differential Diagnoses (7)
| Condition | Key distinction | Shared features |
|---|---|---|
| Schnitzler Syndrome | Urticarial rash (not evanescent salmon-colored). Monoclonal IgM or IgG gammopathy is obligate criterion. Bone pain and abnormal bone imaging characteristic. Typically older onset (median ~50 years). | Quotidian fever, Arthralgia, Leukocytosis, Elevated CRP/ESR, Responds to IL-1 blockade |
| Infections (endocarditis, EBV, CMV, HIV) | Positive blood cultures, serologies, or PCR. Endocarditis shows valvular vegetations on echocardiography. EBV causes atypical lymphocytosis (not neutrophilia). Must be excluded before AOSD diagnosis (Yamaguchi criteria). | Fever, Lymphadenopathy, Elevated inflammatory markers, Hepatosplenomegaly, Pharyngitis |
| Lymphoma (especially non-Hodgkin) | Biopsy shows malignant lymphoid proliferation. Night sweats and weight loss more prominent. Persistent (not evanescent) lymphadenopathy. Elevated LDH out of proportion to other markers. Must be excluded before AOSD diagnosis. | Fever, Lymphadenopathy, Hepatosplenomegaly, Elevated ferritin, Weight loss |
| Systemic Lupus Erythematosus (SLE) | Positive ANA and anti-dsDNA antibodies. Malar rash (not evanescent salmon rash). Hypocomplementemia. Renal involvement (proteinuria, hematuria). AOSD characteristically has negative ANA and RF. | Fever, Arthritis, Serositis, Lymphadenopathy, Elevated ESR |
| Reactive Arthritis | Typically asymmetric oligoarthritis of lower extremities. History of preceding GI or urogenital infection. HLA-B27 positive in many cases. Conjunctivitis, urethritis, enthesitis common. No quotidian fever pattern. | Arthritis, Fever, Elevated inflammatory markers |
| Familial Mediterranean Fever / Periodic Fever Syndromes | Genetic: identified mutations in MEFV (FMF), TNFRSF1A (TRAPS), MVK (HIDS). Family history often present. FMF episodes shorter (12-72 hours) with serositis. Ethnicity-specific prevalence patterns. Childhood onset typical. | Recurrent fever, Arthritis, Elevated acute-phase reactants, Responds to IL-1 blockade, Autoinflammatory pathogenesis |
| Systemic Vasculitis (PAN, granulomatosis with polyangiitis) | ANCA positive in granulomatosis with polyangiitis. Biopsy shows vessel wall inflammation. Organ-specific manifestations (pulmonary nodules, glomerulonephritis, mononeuritis multiplex). Polyarteritis nodosa must be specifically excluded per Yamaguchi criteria. | Fever, Arthralgia, Elevated inflammatory markers, Multi-organ involvement |
Hypotheses (4)
| Hypothesis | Domain | Status | Evidence score | Studies | Evidence for | Evidence against |
|---|---|---|---|---|---|---|
| AOSD is driven by IL-1/IL-18-mediated autoinflammation via NLRP3 inflammasome dysregulation | pathogenesis | leading | 85/100 | 35 |
|
|
| Macrophage activation is the central effector mechanism linking innate immune dysregulation to systemic disease | pathogenesis | leading | 75/100 | 25 |
|
|
| AOSD and systemic juvenile idiopathic arthritis (sJIA) represent a single disease continuum distinguished only by age of onset | nosology | competing | 65/100 | 18 |
|
|
| Genetic susceptibility via HLA polymorphisms and autoinflammatory gene variants predisposes to AOSD | genetics | emerging | 45/100 | 12 |
|
|
Open Questions (6)
- What determines whether AOSD follows a monocyclic, polycyclic, or chronic articular course?
Approximately 23% of patients have monocyclic disease, 38.5% polycyclic, and 38.5% chronic articular. Polyarthritis at onset predicts chronic articular disease, but reliable early predictors are lacking. - What is the initial trigger for NLRP3 inflammasome dysregulation in AOSD?
The downstream inflammasome pathway is well-characterized, but the upstream trigger remains unknown. Infections, environmental factors, and epigenetic changes have been proposed but not proven. - Can early biologic therapy prevent the transition to chronic articular disease?
Expert consensus is shifting toward early biologic use, but no prospective trial has tested whether early IL-1 or IL-6 blockade alters the natural disease course or prevents joint destruction. - Can IL-18 or free IL-18 levels reliably predict MAS before clinical deterioration?
IL-18 is dramatically elevated in AOSD and linked to MAS development. Free IL-18 (not bound by IL-18BP) is specifically elevated in AOSD vs other inflammatory diseases, but prospective validation as a MAS predictor is lacking. - Should IL-1 blockade or IL-6 blockade be first-line biologic based on disease phenotype?
Observational data suggest systemic-dominant disease responds better to IL-1 blockade while chronic articular disease favors IL-6 blockade, but no head-to-head trial has been conducted. - What role do JAK inhibitors play in refractory AOSD?
JAK-STAT signaling is downstream of multiple cytokines involved in AOSD (IL-6, IFN-gamma). Pilot studies of baricitinib and tofacitinib show early promise in biologic-refractory patients, but controlled data are absent.
Complications (6)
| Complication | Risk | Timeframe | Description | Monitoring |
|---|---|---|---|---|
| Macrophage Activation Syndrome (MAS) / Hemophagocytic Lymphohistiocytosis (HLH) | 12-17% | Any time during disease course, often at onset or during flare | The most dangerous complication of AOSD. Characterized by uncontrolled macrophage and T-cell activation leading to a cytokine storm with pancytopenia, disseminated intravascular coagulation, hepatic failure, and multi-organ dysfunction. Mortality rate approximately 10-20%. High systemic score and ferritin are independently associated with MAS occurrence. Paradoxical ferritin drop (from very high levels) and falling ESR with rising CRP may herald onset. | Serial ferritin, fibrinogen, triglycerides, platelet count, liver function. Falling ferritin-to-ESR ratio or rapidly rising ferritin with dropping platelets requires urgent evaluation. |
| AA Amyloidosis | ~3-5% | Years of chronic uncontrolled inflammation | Secondary (AA) amyloidosis results from chronic elevation of serum amyloid A protein during persistent or recurrent inflammation. Primarily affects the kidneys, leading to progressive proteinuria, nephrotic syndrome, and eventually renal failure. More common in the chronic articular phenotype with prolonged disease duration. Effective disease control with biologics may reduce this risk. | Annual serum amyloid A level, urinalysis for proteinuria, serum creatinine. Tissue biopsy (rectal or abdominal fat pad) if suspected. |
| Disseminated Intravascular Coagulation (DIC) | Rare, usually in context of MAS | Acute, during severe flares or MAS | Life-threatening coagulopathy with simultaneous widespread clotting and bleeding. Usually occurs in the context of MAS/HLH. Characterized by thrombocytopenia, prolonged PT/PTT, elevated D-dimer, and decreased fibrinogen. Requires aggressive treatment of the underlying inflammatory process alongside supportive transfusion therapy. | Coagulation studies (PT, PTT, fibrinogen, D-dimer), platelet count during flares. |
| Thrombotic Thrombocytopenic Purpura / Thrombotic Microangiopathy (TTP/TMA) | Rare | During active systemic disease | Thrombotic microangiopathy with microangiopathic hemolytic anemia, thrombocytopenia, and organ damage. May overlap with or be triggered by the same cytokine storm driving MAS. Requires differentiation from DIC and MAS, as treatment approaches differ. Plasma exchange may be necessary alongside immunosuppression. | Peripheral blood smear for schistocytes, LDH, haptoglobin, platelet count, renal function. |
| Pulmonary Complications (pulmonary arterial hypertension, alveolar proteinosis) | Rare but potentially fatal | Variable; may occur during active disease or as late complication | Severe pulmonary complications include pulmonary arterial hypertension (PAH) and pulmonary alveolar proteinosis (PAP), both of which carry significant mortality. Pleural effusions are more common (up to 30%) and usually mild. Pulmonary involvement may be underrecognized and should be considered in patients with unexplained dyspnea. | Chest imaging if symptomatic, echocardiography for PAH screening, pulmonary function tests. |
| Chronic Destructive Arthritis | ~30-40% (in chronic articular phenotype) | Months to years | Progressive joint destruction resembling rheumatoid arthritis, predominantly affecting wrists, knees, ankles, and hips. Occurs in patients with the chronic articular disease pattern. May lead to joint space narrowing, erosions, ankylosis (especially carpal joints), and need for joint replacement. The chronic articular phenotype has the worst functional outcome among the three disease patterns. | Serial radiographs of affected joints, functional assessments, inflammatory markers. Consider early biologic therapy to prevent progression. |
Sources (40)
| Ref | Authors | Title | Journal | Year | Category | Type | Grade | Link |
|---|---|---|---|---|---|---|---|---|
| B3 | Sfriso P, Bindoli S, Galozzi P, et al. | Adult-Onset Still's Disease: molecular pathophysiology and new therapeutic approaches | Int J Mol Sci | 2022 | pathophysiology | narrative review | B | PubMed |
| I1 | Tomaras S, Goetzke CC, Kallinich T, Feist E | Adult-onset Still's disease: clinical aspects and therapeutic approach | J Clin Med | 2021 | clinical | narrative review | B | PubMed |
| I2 | Efthimiou P, Kontzias A, Hur P, et al. | Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies | Semin Arthritis Rheum | 2021 | clinical | narrative review | B | PubMed |
| B5 | Fautrel B, Mitrovic S | Adult-onset Still's disease | Presse Med | 2020 | pathophysiology | narrative review | B | PubMed |
| G2 | Kedor C, Listing J, Zernicke J, et al. | Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled trial | Ann Rheum Dis | 2020 | treatment | RCT | B | PubMed |
| F4 | Inoue N, Shimizu M, Tsunoda S, et al. | Comparative study of interleukin-18 serum levels in adult onset Still's disease and systemic onset juvenile idiopathic arthritis | BMC Immunol | 2019 | pathophysiology | cohort | B | PubMed |
| G4 | Vitale A, Cavalli G, Ruscitti P, et al. | Long-term retention rate of anakinra in adult onset Still's disease and predictive factors for treatment response | Front Pharmacol | 2019 | treatment | cohort | B | PubMed |
| H1 | Ruscitti P, Cipriani P, Liakouli V, et al. | Managing adult-onset Still's disease: the effectiveness of high-dosage of corticosteroids as first-line treatment | Clin Exp Rheumatol | 2019 | treatment | cohort | C | PubMed |
| J1 | Wang MY, Jia JC, Yang CD, Hu QY | Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review | Chin Med J | 2019 | pathophysiology | narrative review | B | PubMed |
| B1 | Feist E, Mitrovic S, Fautrel B | Mechanisms, biomarkers and targets for adult-onset Still's disease | Nat Rev Rheumatol | 2018 | pathophysiology | narrative review | A | PubMed |
| B2 | Giacomelli R, Ruscitti P, Shoenfeld Y | A comprehensive review on adult onset Still's disease | J Autoimmun | 2018 | pathophysiology | narrative review | B | PubMed |
| C4 | Sigrist S, Stand A, Gerfaud-Valentin M, et al. | Evidence for genetic overlap between adult onset Still's disease and hereditary periodic fever syndromes | Rheumatology | 2018 | genetics | cohort | B | DOI |
| D2 | Fautrel B, Stand A, Golmard JL, et al. | Validation of the Fautrel classification criteria for adult-onset Still's disease | Semin Arthritis Rheum | 2018 | diagnostics | cohort | B | PubMed |
| G3 | Kaneko Y, Kameda H, Ikeda K, et al. | Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial | Ann Rheum Dis | 2018 | treatment | RCT | B | PubMed |
| G6 | Gabay C, Fautrel B, Rech J, et al. | Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease | Ann Rheum Dis | 2018 | treatment | cohort | C | PubMed |
| H4 | Efthimiou P, Kadavath S, Engel B | Complications of adult-onset Still's disease and their management | Expert Rev Clin Immunol | 2018 | clinical | narrative review | B | PubMed |
| B4 | Chen DY, Lan JL, Lin FJ, Hsieh TY | Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease | J Rheumatol | 2017 | pathophysiology | cohort | B | PubMed |
| C1 | Asano T, Furukawa H, Sato S, et al. | Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still's disease | Arthritis Res Ther | 2017 | genetics | cohort | B | PubMed |
| H2 | Ruscitti P, Iacono D, Ciccia F, et al. | Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rate and its causes of death | Medicine | 2017 | clinical | cohort | B | PubMed |
| F2 | Girard C, Rech J, Brown M, et al. | Elevated serum levels of free interleukin-18 in adult-onset Still's disease | Rheumatology | 2016 | pathophysiology | cohort | B | PubMed |
| H3 | Lenert A, Yao Q | Macrophage activation syndrome complicating adult onset Still's disease: a single center case series and comparison with literature | Semin Arthritis Rheum | 2016 | clinical | case series | C | PubMed |
| G5 | Jamilloux Y, Gerfaud-Valentin M, Henry T, Seve P | Treatment of adult-onset Still's disease: a review | Ther Clin Risk Manag | 2015 | treatment | narrative review | B | PubMed |
| K2 | Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P | Adult-onset Still's disease | Autoimmun Rev | 2014 | clinical | narrative review | B | PubMed |
| C5 | Wouters JM, Reekers P, van de Putte LB | The association of TNFRSF1A gene and MEFV gene mutations with adult onset Still's disease | Clin Exp Rheumatol | 2012 | genetics | cohort | C | DOI |
| F1 | Colafrancesco S, Priori R, Alessandri C, et al. | IL-18 Serum Level in Adult Onset Still's Disease: A Marker of Disease Activity | Int J Inflam | 2012 | pathophysiology | cohort | B | PubMed |
| F3 | Colafrancesco S, Priori R, Valesini G, et al. | Ferritin in adult-onset Still's disease: just a useful innocent bystander? | Int J Inflam | 2012 | pathophysiology | narrative review | B | PubMed |
| G1 | Nordstrom D, Knight A, Luukkainen R, et al. | Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease: an open, randomized, multicenter study | J Rheumatol | 2012 | treatment | RCT | B | PubMed |
| K1 | Jung JY, Kim MY, Suh CH, Kim HA | Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease | J Rheumatol | 2010 | pathophysiology | cohort | B | PubMed |
| A4 | Fautrel B | Adult-onset Still disease | Best Pract Res Clin Rheumatol | 2008 | clinical | narrative review | B | PubMed |
| I3 | Kontzias A, Efthimiou P | Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances | Drugs | 2008 | treatment | narrative review | B | PubMed |
| A3 | Efthimiou P, Paik PK, Bielory L | Diagnosis and management of adult onset Still's disease | Ann Rheum Dis | 2006 | clinical | narrative review | B | PubMed |
| A2 | Fautrel B, Zing E, Golmard JL, et al. | Proposal for a new set of classification criteria for adult-onset still disease | Medicine (Baltimore) | 2002 | diagnostics | case series | B | PubMed |
| C2 | Sugiura T, Kawaguchi Y, Harigai M, et al. | Association between adult-onset Still's disease and interleukin-18 gene polymorphisms | Genes Immun | 2002 | genetics | cohort | B | DOI |
| D1 | Fautrel B, Le Moel G, Saint-Marcoux B, et al. | Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease | J Rheumatol | 2001 | diagnostics | cohort | B | DOI |
| E3 | Masson C, Le Loet X, Liote F, et al. | Adult Still's disease. Part II. Management, outcome, and prognostic factors | Rev Rhum Engl Ed | 1996 | clinical | cohort | C | PubMed |
| E1 | Magadur-Joly G, Billaud E, Barrier JH, et al. | Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France | Ann Rheum Dis | 1995 | epidemiology | cohort | C | PubMed |
| A1 | Yamaguchi M, Ohta A, Tsunematsu T, et al. | Preliminary criteria for classification of adult Still's disease | J Rheumatol | 1992 | diagnostics | case series | B | DOI |
| E2 | Cush JJ, Medsger TA Jr, Christy WC, et al. | Adult-onset Still's disease: clinical course and outcome | Arthritis Rheum | 1987 | clinical | case series | C | PubMed |
| C3 | Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ | Adult-onset Still's disease: disease course and HLA associations | Arthritis Rheum | 1986 | genetics | case series | C | DOI |
| J2 | Bywaters EG | Still's disease in the adult | Ann Rheum Dis | 1971 | clinical | case series | C | PubMed |
Pathophysiology Narrative
AOSD is driven by dysregulated activation of the innate immune system. Danger signals — both pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) — are transmitted to macrophages and neutrophils via Toll-like receptors (TLRs), which excessively activate the NLRP3 inflammasome in patients with a predisposing genetic background.
The NLRP3 inflammasome serves as a central hub: upon activation, it recruits ASC adaptor proteins and activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their bioactive forms. Expression levels of NLRP3, caspase-1, and IL-1β are all significantly elevated in peripheral blood mononuclear cells from AOSD patients. This excessive inflammasome activation leads to a cytokine storm involving IL-1β, IL-18, IL-6, IL-8, TNF-α, and IFN-γ.
IL-18 plays a particularly prominent role in AOSD — serum levels can be up to 1000-fold higher than in other rheumatic diseases, making it the most specifically elevated cytokine. IL-18 drives macrophage activation, IFN-γ production by Th1 cells, and is closely linked to the development of macrophage activation syndrome (MAS). IL-6 contributes to systemic inflammation, hepatic acute-phase reactant production (including ferritin and CRP), and joint destruction.
The characteristic hyperferritinemia of AOSD (often >1000 ng/mL, sometimes >10,000 ng/mL) results from cytokine-mediated upregulation of ferritin synthesis at transcriptional and translational levels by IL-1β, IL-6, IL-18, TNF-α, IFN-γ, and M-CSF. The low glycosylated ferritin fraction (<20%) reflects saturation of glycosylation machinery during massive hepatic ferritin production.
Neutrophils in AOSD patients have enhanced capacity to form neutrophil extracellular traps (NETs), which activate pro-inflammatory macrophages and further stimulate the NLRP3 inflammasome, creating a self-amplifying loop. S100 proteins (calprotectin/S100A8/A9 and S100A12), released by activated phagocytes, further activate TLR4 signaling and contribute to the inflammatory cascade.
Genetic Basis Narrative
AOSD is classified as a multigenic (complex) autoinflammatory disorder. No single causative gene has been identified, but multiple genetic susceptibility factors have been described across different populations.
HLA associations vary by ethnicity: HLA-DRB1*15:01 and HLA-DR5 are associated with susceptibility in Japanese populations, HLA-DR4 in Dutch patients, and HLA-B17, HLA-B18, HLA-B35, and HLA-DR2 in French cohorts. These HLA associations — unusual for autoinflammatory diseases — suggest involvement of the adaptive immune system alongside innate immunity.
Polymorphisms in the IL-18 gene promoter region affect susceptibility: the S01/S01 diplotype configuration is a significant genetic risk factor. IL-18 gene -607 promoter polymorphisms have functional associations with disease course in Chinese patients, with certain genotypes protective against disease severity and chronic arthritis.
Variations in the MEFV gene (encoding pyrin, the Familial Mediterranean Fever gene) have been found at elevated frequency in AOSD patients across Korea, Japan, Germany, and Turkey, with 15–63% of patients carrying variants depending on the population. This suggests genetic overlap between AOSD and hereditary periodic fever syndromes. Rare variants in TNFRSF1A (TRAPS gene) are also associated with AOSD, especially in patients with more severe disease courses.
A next-generation sequencing study of 24 AOSD patients found that those with genetic variants in autoinflammatory disease genes were more likely to require biologic therapy, suggesting genetic testing may have prognostic value. Polymorphisms in genes encoding macrophage migration inhibitory factor (MIF) and serum amyloid A1 may also contribute to susceptibility.